scholarly journals Knowledge and Perception of Cord Blood Bank among Lebanese Population

2016 ◽  
Vol 3 (3) ◽  
pp. 307
Author(s):  
Bassam Charif Hamdar ◽  
Rita Abla
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Blood Cells ◽  
Arab World ◽  
Genetic Diseases ◽  
White Blood Cells ◽  
Blood Disorders ◽  
Blood Stem Cells ◽  
Cord Blood Cells ◽  
New Research

<p class="Default"><em>The cord blood cells are hematopoietic</em><em> </em><em>stem cells which can differentiate only into blood cells. In other words, cord blood stem cells are blood cell precursors which can form red blood cells, white blood cells, and platelets. Nowadays, these cells are being used to treat blood and immune system that associated with genetic diseases, cancers, and blood disorders.</em><em></em></p><p class="Default"><em>Due to the great value of the stem cells, new research and technology show that it is highly recommended that cord blood cells are reserved for the future use. This paper will shed light on the important aspects and the ability of doing blood cord bank in Lebanon.</em><em></em></p><p class="Default"><em>This paper is exploratory in nature and its mere purpose is to focus on some aspects that were first not known in the Arab world in general and in Lebanon in specific. To achieve all the above, a questionnaire has been designed and delivered to the sample via different means.</em><em></em></p><p class="Default"><em>An overview of this paper reveals some understanding about the level of awareness achieved by the Lebanese citizens. Other objectives came into play and some of those were the relation between banking cord blood and religion.</em><em></em></p><p class="Default"><em>The outcome of this paper is a practicability study of blood cord bank which is related two concepts, with and against, by revealing the pros and cons of this subject.</em><em></em></p>

Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times

2021 ◽  
Vol 15 ◽  
Author(s):  
Suman Kumar Ray ◽  
Sukhes Mukherjee
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Cells ◽  
Hematopoietic Stem ◽  
Blood Stem Cells ◽  
Cord Blood Stem Cells ◽  
Cord Blood Cells ◽  
Stem Cell Treatment

: The umbilical cord blood is usually disposed of as an unwanted material after parturition; however, today, it is viewed as a regenerative medication so as to create the organ tissues. This cord blood gathered from the umbilical cord is made up of mesenchymal stem cells, hematopoietic stem cells, and multipotent non-hematopoietic stem cells having many therapeutic effects as these stem cells are utilized to treat malignancies, hematological ailments, inborn metabolic problem, and immune deficiencies. Presently, numerous clinical applications for human umbilical cord blood inferred stem cells, as stem cell treatment initiate new research. These cells are showing such a boon to stem cell treatment; it is nevertheless characteristic that the prospect of conservation of umbilical cord blood is gaining impetus. Current research works have demonstrated that about 80 diseases, including cancer, can be treated or relieved utilizing umbilical cord blood stem cells, and every year, many transplants have been effectively done around the world. However, in terms of factors, including patient selection, cell preparation, dosing, and delivery process, the treatment procedure for therapy with minimally manipulated stem cells can be patented. It is also worth thinking about how this patent could affect cord blood banks. Meanwhile, the utilization of cord blood cells is controversial and adult-derived cells may not be as successful, so numerous clinicians have begun working with stem cells that are acquired from umbilical cord blood. This review epitomizes a change in outlook from what has been completed with umbilical cord blood cell research and cord blood banking on the grounds that cord blood cells do not require much in the method of handling for cryopreservation or for transplantation in regenerative medicine.

scholarly journals Changes of intracardiac hemodynamics in patients with decreased myocardial contractility at transplantation of cord blood stem cells

2015 ◽  
Vol 3 (1) ◽  
pp. 24-27
Author(s):  
A. Gabrielyan ◽  
A. Yakushev ◽  
A. Matyashchuk ◽  
T. Domanskiy ◽  
I. Kudlay ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Blood Cells ◽  
Myocardial Contractility ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Venous Stasis ◽  
Blood Stem Cells ◽  
Cord Blood Stem Cells ◽  
Cord Blood Cells

Experiments on animals have shown an effectiveness of cord blood stem cells (SCs) in restoration of myocardial contractility. But there is not enough information about the use of this SCs type at heart lesion in people. Therefore, the aim of this study was to analyze the effect of cord blood SCs transplantation on impaired myocardial contractility of patients with chronic heart failure.Materials and methods. According to the data echocardiography we analyzed the changes of intracardiac hemodynamics in patients with decreased myocardial contractility, who underwent intravenous transplantation of cord blood stem cells in case of ineffective traditional conservative therapy schemes of heart failure (HF).Results. Left ventricular ejection fraction before cord blood stem cells transplantation was 22.0 ± 5.0 %, 1 month after SC transplantation – 22.3 ± 6.5%, and in 3 months – 28.5 ± 7.8 % (p < 0.05). The average stroke index increased from 21.3 ± 3.5 ml/m2 before transplantation up to 29.0 ± 8.5 ml/m2 3 months after transplantation SC (p < 0.05). Statistically significant changes of diastolic function parameters (index e’, E/A, E/e’) and venous stasis have not been established. Before transplantation local cell contractility index (LCI) of basal and middle segments was 2.43 points; 1 month after transplantation LCI decreased to 2.38, and after 3 months – up to 2.18 points (p <0.05).Conclusion. In a short term (1-3 months) after transplantation of cord blood cells there was demonstrated a partial restoration of parameters that characterize left ventricular systolic function, and a significant improvement of impaired heart rate mechanics. No negative effects, complications and side effects have been recorded in short periods of observation after transplantation of cord blood cells.

scholarly journals A Novel Hybrid Transplantation with Autologous Hematopoietic Stem Cells and Matched Unrelated Cord Blood Stem Cells Is Effecttive and Safe for Relapsed or Refractory Lymphoma: A Pilot Study

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5713-5713
Author(s):  
Yongqian Jia ◽  
Jian Li ◽  
Huan Tao ◽  
Pu Kuang ◽  
Jie Ji ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cord Blood ◽  
Cell Transplantation ◽  
Blood Cells ◽  
Hematopoietic Stem ◽  
Blood Stem Cells ◽  
Refractory Lymphoma ◽  
Cord Blood Cells

Backgroud: Autologous hematopoietic stem cell transplantation (ASCT) is widely recommended for relapsed or refractory lymphoma as an important second-line salvage therapy. Post-transplant relapse is a main issue due to its lacking of the graft versus tumor effects with routine ASCT. Hereby we present a novel hybrid transplantation with autologous stem cells and matched unrelated cord blood cells for relapsed or refractory lymphoma. Method A total of 37 patients with relapsed or refractory lymphoma were enrolled from July 2013 to May 30, 2019 in the West China Hospital of Sichuan University. The autologous peripheral blood stem cells were collected and freezed. HLA matched cord blood cells were searched and provided by the Sichuan Cord Blood Bank. Autologous peripheral blood stem cell transplantation (APBSCT) were infused at day 0 and the selected cord blood cells were infused at day+1 with standard BEAM conditioning regimen. Result The gender distribution was 51.4% female and 48.6% male.The Median age was 37 years old (16-65 years old). The disease characteristics: relapsed or refractory HL 14 cases, relapsed or refractory DLBCL 9 cases, relapsed Burkitt lymphoma 1 case, HGBL with DHL 1 case, DEL 4 cases, Nos 2 cases, DLBCL with high IPI 3 cases. Advanced nasal NK/T cell lymphoma 2 cases, relapdsed EBV-LPD 1 case. The median number of CD34*106/kg for ASCT was 2.35 (1.32-4.58). The median number of total nucleated cord blood cells was 10.2*108 (6.13-17.9) and the CD34+ cord blood cells was 2.72*106 (1.08-5.2). HLA-identical related donor (6/6) was 10.81%, one-antigen-mismatched (5/6) was 72.98%, two-antigen-mismatched (4/6) was 16.21%. All patients were transplanted succesfully with neutrophil recovery of 11days (8-29) and platelet recovery of 14 days (10-120). An early transplanted syndrom with rash or fever were observed in 7 pts (18.9%), while a delayed neutropenia were observed in 5 pts (13.5%). All symptoms were relieved with prednisone therapy. 2 out of 10 pts examined showed sign of microchimerism at 1 month post transplant. With a median 28 months of follow-up (2-73 months), our hybrid transplantation for R/R lymphoma showed that the relapse-free surviaval (RFS) is 90.4% ,and the overall survival (OS) is 86.4%, which is improved remarkablly. The overall OS and RFS were significant different between complete remission (CR) and Non-CR before transplantation (p= 0.002 for OS; p= 0.015 for RFS), but there was no significant difference in the subgroups of HL and NHL. Conclusion This preliminary pilot study suggested that the hybrid stem cell transplantation with autologous stem cells and matched cord blood stem cells is effective and safe for the treatment of high risk lymphoma with limited controlable immuno reactions. Disclosures Zhang: the National Natural Science Foundation of China: Research Funding.

Hepatocyte differentiation from embryonic stem cells and umbilical cord blood cells

2005 ◽  
Vol 12 (3) ◽  
pp. 196-202 ◽  
Author(s):  
Kenichi Teramoto ◽  
Kinji Asahina ◽  
Yuji Kumashiro ◽  
Sei Kakinuma ◽  
Ryoko Chinzei ◽  
...  
Keyword(s):  
Stem Cells ◽  
Embryonic Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Cells ◽  
Embryonic Stem ◽  
Hepatocyte Differentiation ◽  
Cord Blood Cells ◽  
Umbilical Cord Blood Cells

Myogenic Potential of Mesenchymal Stem Cells - the Case of Adhesive Fraction of Human Umbilical Cord Blood Cells

2013 ◽  
Vol 8 (1) ◽  
pp. 82-90 ◽  
Author(s):  
Iwona Grabowska ◽  
Wladyslawa Streminska ◽  
Katarzyna Janczyk-Ilach ◽  
Eugeniusz K. Machaj ◽  
Zygmunt Pojda ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord Blood ◽  
Blood Cells ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Myogenic Potential ◽  
Cord Blood Cells ◽  
Umbilical Cord Blood Cells

scholarly journals Isolation of mesenchymal stromal/stem cells from cryopreserved umbilical cord blood cells

2017 ◽  
Vol 57 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Sumie Fujii ◽  
Yasuo Miura ◽  
Masaki Iwasa ◽  
Satoshi Yoshioka ◽  
Aya Fujishiro ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Cells ◽  
Cord Blood Cells ◽  
Umbilical Cord Blood Cells ◽  
Stromal Stem Cells

Mesenchymal Stem Cells from the Wharton’s Jelly of Umbilical Cord Segments Support the Maintenance of Long Term Culture-Initiating Cells from Cord Blood.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3650-3650
Author(s):  
Kent W. Christopherson ◽  
Tiki Bakhshi ◽  
Shamanique Bodie ◽  
Shannon Kidd ◽  
Ryan Zabriskie ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Blood Cells ◽  
Hematopoietic Stem ◽  
Cord Blood Cells

Abstract Hematopoietic Stem Cells (HSC) are routinely obtained from bone marrow, mobilized peripheral blood, and umbilical Cord Blood. Traditionally, adult bone marrow has been utilized as a source of Mesenchymal Stem Cells (MSC). Bone marrow derived MSC (BM-MSC) have previously been shown to maintain the growth of HSC obtained from cord blood and have been utilized for cord blood expansion purposes. However, the use of a mismatched BM-MSC feeder stromal layer to support the long term culture of cord blood HSC is not ideal for transplant purposes. The isolation of MSC from a novel source, the Wharton’s Jelly of Umbilical Cord segments, was recently reported (Romanov Y, et al. Stem Cells.2003; 21: 105–110) (Lee O, et al. Blood.2004; 103: 1669–1675). We therefore hypothesized that Umbilical Cord derived MSC (UC-MSC) have the ability to support the long term growth of cord blood derived HSC similar to that previously reported for BM-MSC. To test this hypothesis, MSC were isolated from the Wharton’s Jelly of Umbilical Cord segments and defined morphologically and by cell surface markers. UC-MSC were then tested for their ability to support the growth of pooled CD34+ cord blood cells in long term culture - initiating cell (LTC-IC) assays as compared to BM-MSC. We observed that like BM-MSC, CB-MSC express a defined set of cell surface markers. By flow cytometry we determined that that both UC-MSC and BM-MSC are positive for CD29, CD44, CD73, CD90, CD105, CD166, HLA-A and negative for CD45, CD34, CD38, CD117, HLA-DR expression. Utilizing Mitomycin C treated (200 μM, 15 min.) UC-MSC from multiple donors as a feeder layer we observed that UC-MSC have the ability to support the maintenance of long term hematopoiesis during the LTC-IC assay. Specifically, UC-MSC isolated from separate umbilical cord donors support the growth of 69.6±11.9 (1A), 31.7±3.9 (2B), 67.0±13.5 (3A), and 38.5±13.7 (3B) colony forming cells (CFC) per 1×104 CD34+ cord blood cells as compared to 64.0±4.2 CFC per 1×104 CD34+ cord blood cells supported by BM-MSC (Mean±SEM, N=4 separate segments from three different donors). Thus, Umbilical Cord derived Mesenchymal Stem Cells, a recently described novel source of MSC, have the ability to support long term maintenance of Hematopoietic Stem Cells, as defined by the LTC-IC assay. These results may have potential therapeutic application with respect to ex vivo stem cell expansion of Cord Blood Hematopoietic Stem Cells utilizing a Mesenchymal Stem Cell stromal layer. In addition, these data suggest the possibility of co-transplantation of matched Mesenchymal and Hematopoietic Stem Cells from the same umbilical cord and cord blood donor respectively. Lastly, these results describe a novel model system for the future study of the interaction between Cord Blood Hematopoietic Stem Cells and the appropriate supportive microenvironment represented by the Umbilical Cord - Mesenchymal Stem Cells.

Sign in / Sign up

Export Citation Format

Share Document